Aap Implantate Ag · XETR:AAQ1
Aap Implantate — German Equity Forum 2019
24 slides from Aap Implantate's conference presentation, Nov 26, 2019
Slide 1: aap Implantate AG Corporate Presentation
aap Implantate AG Corporate Presentation German Equity Forum 2019 Rubino Di Girolamo, CEO Marek Hahn, CFO Frankfurt am Main, November 26, 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: Investment Highlights
Investment Highlights aap is a German-based medtech company, a pure player in trauma with exciting and 1 IP-protected platform technologies addressing unmet needs in orthopedics aap is a front runner in antibacterial silver coating technology for implantable medical 2 devices which reduces surgical
Slide 4: aap at a Glance
aap at a Glance Pure player in trauma Organisation Technologies ➢ Globally operating medical device company based in Germany ➢ Founded in 1990 Antibacterial Resorbable ➢ 147 Employees (30/09/2019) Silver Coating Magnesium Three innovative and IP- ➢ Distribution: Implants protected platform • Germany
Slide 5: The Way Ahead (1/2)
The Way Ahead (1/2) Key success factors 2019 and ahead ➢ Accelerated Top-line Growth via ➢ Increase in domestic and international sales as a result of efforts made in 2018 and 2019 ➢ Establish new US team with focus on listing at national contracts and active training of clients ➢ Selected distribut
Slide 6: The Way Ahead (2/2)
The Way Ahead (2/2) Key success factors 2019 and ahead ➢ Silver Coating Technology ➢ Start human clinical study as prerequisite for market approval ➢ Global partnerships with leading global medical technology companies ➢ Update 9M: ➢ BfArM approval received for human clinical study ➢ EUR 2.7m fundin
Slide 7: Platform Technology – LOQTEQ
Platform Technology – LOQTEQ ➢ LOQTEQ® System (clinically proven and rolled-out in key markets) ➢ Comprehensive trauma product portfolio with more than 90% indication coverage ➢ Strong IP protection ➢ Products providing clinical as well as economical competitive advantages compared to global leaders
Slide 8: Value Creation
Value Creation Approach to exploit the market with Approach Successes Future Growth ➢ Direct sales force to ➢ Comprehensive portfolio (>90% ➢ Increase of market hospitals, buying indication coverage) with listing at presence with >20% syndicates, and hospital major hospital groups and group sales gr
Slide 9: Platform Technology – Silver Coating
Platform Technology – Silver Coating ➢ Silver Coating Technology (game changer technology) ➢ Front runner in developing antibacterial silver coating technology for implantable medical devices ➢ Strong IP protection ➢ Technology and product development accomplished; approval in process ➢ Final stage
Slide 10: Value Creation
Value Creation Approach to exploit the market with Silver Coating Approach Successes Future Value Creation ➢ Own distribution and ➢ GER: BfArM approval ➢ Distribution of silver-coated partnerships with received for human aap products global companies clinical study; ethics ➢ Co-development and commi
Slide 11: Platform Technology – Magnesium Implants
Platform Technology – Magnesium Implants ➢ Coated Resorbable Magnesium Implant Technology (open for co-investment) ➢ Avoids second operations to remove implants thanks to resorption of implants in the body after fracture healing ➢ Strong IP protection ➢ Technology and products under development ➢ Co
Slide 12: Value Creation
Value Creation Approach to exploit the market with Magnesium Implants Approach Successes Future Value Creation ➢ Joint product ➢ Own alloy with good ➢ Joint product development development and biomechanical properties and distribution agreement distribution with and high biocompatibility, with techn
Slide 13: Value Creation
Value Creation Sum of the parts – strategic framework ➢ Potential to be first mover in trauma application ➢ Wide range of applications outside trauma (i.e. cardiology) ➢ Increasing interest by global companies ➢ Valuation: Assessment by PWC on licensing opportunities shows big value potential ➢ Lead
Slide 14: Many thanks for your attention!
Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app:
Slide 15: Appendix
Appendix qos
Slide 16: Update 9M/2019
Update 9M/2019 ➢ Sales ➢ Continuation of solid growth trend (+6% yoy to EUR 8.7m) ➢ Driven by Germany (+5% yoy) and international business (+7% yoy), further stabilization in USA (+1% yoy) ➢ USA with positive development since end of September 2019: number of weekly cases almost doubled yoy and incr
Slide 17: Update 9M/2019
Update 9M/2019 ➢ LOQTEQ® ➢ FDA approval for polyaxial LOQTEQ® VA foot and calcaneus systems – Launch in USA and further markets planned for beginning of 2020 ➢ Continuous focus on adaption of processes and documents to new regulatory requirements of MDR and development of sterile packaging for impla
Slide 18: aap by numbers
aap by numbers Sales and earnings Sales (in KEUR) 9M/2019 9M/2018 Change Trauma 8,675 8,235 +5% Germany 2,193 2,080 +5% USA1 1,367 1,358 +1% USA Distributors 1,297 1,297 0% USA Global Partners 70 61 +15% International (without USA) 5,115 4,797 +7% Europe (without Germany) 1,561 1,333 +17% BRICS stat
Slide 19: aap by numbers
aap by numbers Capital and cash structure Capital Structure (in EUR million) 30/09/2019 31/12/2018 Total Assets 39.8 42.2 Equity Ratio 80% 83% Cash Structure (in EUR million) 30/09/2019 31/12/2018 Cash (per B/S) 3.7 4.3 Net Cash (per B/S) 1.4 4.0 Cash holdings (incl. Restricted Cash) 4.41 7.32 Net C
Slide 20: Shareholder Structure
Shareholder Structure* (Shareholdings in aap ≥ 3%, according to our information) ➢ High degree of stability with a base of long-term oriented investors 16.26% Ratio Capital Management B.V., Netherlands Noes Beheer B.V., Netherlands Jürgen W. Krebs, Switzerland 13.57% 50.79% Deepblue Holding AG, Swit
Slide 21: Notes
Notes cap
Slide 22: Notes
Notes cap
Slide 23: Notes
Notes cap
Slide 24: Lorenzweg 5, Berlin – Investor Relations
Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: